Glaukos (NYSE:GKOS) Research Coverage Started at UBS Group

UBS Group started coverage on shares of Glaukos (NYSE:GKOS) in a research note released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a neutral rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently issued reports on GKOS. Needham & Company LLC boosted their price objective on shares of Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. JPMorgan Chase & Co. raised their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. William Blair reissued an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research report on Wednesday, July 1st. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.33.

Glaukos Stock Performance

GKOS opened at $167.10 on Tuesday. The company’s 50 day moving average is $137.20 and its 200 day moving average is $124.78. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The company has a market cap of $9.81 billion, a price-to-earnings ratio of -51.42 and a beta of 0.75. Glaukos has a 12-month low of $73.16 and a 12-month high of $184.00.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.33%. The business had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. During the same period in the prior year, the company earned ($0.24) earnings per share. The firm’s revenue was up 49.6% on a year-over-year basis. On average, equities research analysts predict that Glaukos will post -0.57 EPS for the current year.

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 16th. The stock was sold at an average price of $160.00, for a total value of $1,600,000.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at $7,024,960. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the transaction, the director owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 40,000 shares of company stock valued at $6,028,800 in the last ninety days. 5.90% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Horizon Corp boosted its stake in Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos in the fourth quarter worth $28,000. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 226 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 215 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported record second-quarter revenue of $185.6 million, up approximately 50% year over year and well above the roughly $151 million analyst consensus. The company’s quarterly loss narrowed to $0.14 per share from $0.24 a year earlier, beating expectations. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
• Positive Sentiment: Growth was led by the iDose TR sustained-release glaucoma treatment and Epioxa, supporting stronger sales momentum and improved gross profit. Management now expects 2026 net sales of $680 million to $700 million, well above the approximately $630 million consensus forecast. iDose TR sales are projected at $275 million to $280 million. Glaukos outlines 2026 net sales outlook
• Positive Sentiment: BTIG Research raised its price target from $164 to $193 and maintained a Buy rating, indicating continued confidence in Glaukos’s commercial growth potential. BTIG raises Glaukos price target
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $150 price target, suggesting the strong outlook is partly reflected in the valuation. Glaukos remains unprofitable, with a negative net margin, while operating cash flow was negative during the quarter.
• Negative Sentiment: Insider-trading data showed continued selling, including a $1.6 million CFO transaction conducted under a pre-arranged Rule 10b5-1 plan. While not necessarily a signal of deteriorating fundamentals, the sales may temper investor sentiment after the stock’s substantial run-up.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.